CGRP is thought to play a key role in cluster headache11,12

Elevated plasma levels of calcitonin gene-related peptide (CGRP) are exhibited during episodic cluster headache attacks12

  • CGRP, expressed in trigeminal ganglion neurons, is involved with many cluster headache symptoms11,12
  • CGRP levels have been shown to normalize after treatment with sumatriptan and oxygen in patients with cluster headache12

CGRP has been shown to trigger cluster headache attacks11

In a study of patients with cluster headache11:

Patient infographic

Infusion of CGRP provoked cluster headache attacks during an active cluster period in 8 out of 9 patients with episodic cluster headache11

View the role CGRP plays in episodic cluster headache

References: 1. Leone M, Giustiniani A, Cecchini AP. Cluster headache: present and future therapy. Neurol Sci. 2017;38(suppl 1):S45-S50. 2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. 3. Hoffman J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75-83. 4. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 5. Lund N, Barloese M, Petersen A, et al. Chronobiology differs between men and women with cluster headache, clinical phenotype does not. Neurology. 2017;88:1069-1076. 6. Torkamani M, Ernst L, Cheung LS, et al. The neuropsychology of cluster headache: cognition, mood, disability, and quality of life of patients with chronic and episodic cluster headache. Headache. 2015;55:287-300. 7. Klapper JA, Klapper A, Voss T. The misdiagnosis of cluster headache: a nonclinic, population-based, internet survey. Headache. 2000;40:730-735. 8. van Vliet JA, Eekers PJE, Haan J, et al. Features involved in the diagnostic delay of cluster headache. J Neurol Neurosurg Psychiatry. 2003;74:1123-1125. 9. Voiticovschi-Iosob C, Allena M, De Cillis I, et al. Diagnostic and therapeutic errors in cluster headache: a hospital-based study. J Headache Pain. 2014;15:56. doi:10.1186/1129-2377-15-56. 10. Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52:99-113. 11. Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75(10):1187-1197. 12. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache: neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427-434.

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.